Quoin Pharmaceuticals (QNRX) Competitors $14.89 +1.35 (+9.97%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$14.80 -0.09 (-0.60%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNRX vs. DRIO, POCI, MODD, STRR, NRXS, CLGN, RVP, VVOS, NXL, and COCHShould you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include DarioHealth (DRIO), Precision Optics (POCI), Modular Medical (MODD), Star Equity (STRR), NeurAxis (NRXS), CollPlant Biotechnologies (CLGN), Retractable Technologies (RVP), Vivos Therapeutics (VVOS), Nexalin Technology (NXL), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry. Quoin Pharmaceuticals vs. Its Competitors DarioHealth Precision Optics Modular Medical Star Equity NeurAxis CollPlant Biotechnologies Retractable Technologies Vivos Therapeutics Nexalin Technology Envoy Medical Quoin Pharmaceuticals (NASDAQ:QNRX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Do institutionals & insiders hold more shares of QNRX or DRIO? 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of DarioHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, QNRX or DRIO? Quoin Pharmaceuticals has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Do analysts rate QNRX or DRIO? DarioHealth has a consensus target price of $40.00, suggesting a potential upside of 206.98%. Given DarioHealth's stronger consensus rating and higher possible upside, analysts plainly believe DarioHealth is more favorable than Quoin Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00DarioHealth 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media refer more to QNRX or DRIO? In the previous week, Quoin Pharmaceuticals had 5 more articles in the media than DarioHealth. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 2 mentions for DarioHealth. Quoin Pharmaceuticals' average media sentiment score of 0.55 beat DarioHealth's score of 0.25 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DarioHealth 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is QNRX or DRIO more profitable? Quoin Pharmaceuticals has a net margin of 0.00% compared to DarioHealth's net margin of -162.73%. DarioHealth's return on equity of -65.89% beat Quoin Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Quoin PharmaceuticalsN/A -210.50% -99.41% DarioHealth -162.73%-65.89%-39.03% Which has better valuation & earnings, QNRX or DRIO? Quoin Pharmaceuticals has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuoin PharmaceuticalsN/AN/A-$8.96M-$41.45-0.36DarioHealth$27.04M1.09-$42.75M-$13.20-0.99 SummaryDarioHealth beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Quoin Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNRX vs. The Competition Export to ExcelMetricQuoin PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.76M$3.02B$6.21B$10.54BDividend YieldN/A54.20%5.70%4.81%P/E Ratio-0.3623.3185.7027.13Price / SalesN/A588.05582.68179.32Price / CashN/A169.4137.1060.81Price / Book0.425.3212.236.52Net Income-$8.96M$33.06M$3.33B$276.93M7 Day Performance-27.37%2.29%1.17%1.93%1 Month Performance93.38%7.35%6.85%2.19%1 Year Performance-49.95%-5.13%58.93%34.62% Quoin Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNRXQuoin Pharmaceuticals1.7278 of 5 stars$14.89+10.0%N/A-49.9%$8.76MN/A-0.364News CoverageAnalyst ForecastInsider TradeDRIODarioHealth2.062 of 5 stars$14.38-3.7%$40.00+178.2%-36.7%$32.64M$27.04M-1.09200Gap DownPOCIPrecision Optics0.234 of 5 stars$4.23-0.2%N/A-1.2%$32.61M$19.09M-5.0480MODDModular Medical1.1074 of 5 stars$0.58-5.8%N/A-73.9%$32.01MN/A-1.1420Analyst ForecastShort Interest ↓Gap UpHigh Trading VolumeSTRRStar Equity1.1071 of 5 stars$11.13-0.9%$5.00-55.1%+173.0%$30.66M$137.86M-8.561,300NRXSNeurAxis1.9936 of 5 stars$3.03-1.3%$7.00+131.0%-1.3%$29.92M$3.22M-1.6519CLGNCollPlant Biotechnologies1.9367 of 5 stars$2.32+3.6%$11.50+395.7%-44.6%$29.51M$510K-2.0570News CoverageGap UpRVPRetractable Technologies2.478 of 5 stars$0.92-5.2%N/A+21.5%$27.46M$38.16M-1.70240News CoveragePositive NewsShort Interest ↓VVOSVivos Therapeutics1.5273 of 5 stars$3.18+0.3%$4.92+54.6%+8.6%$23.85M$15.03M-1.89160Negative NewsShort Interest ↑NXLNexalin Technology2.6131 of 5 stars$1.29-3.7%$5.00+287.6%+20.6%$22.77M$170K-1.703Short Interest ↓COCHEnvoy Medical2.0289 of 5 stars$0.92+2.2%$9.50+934.5%-69.5%$21.87M$220K-0.6434 Related Companies and Tools Related Companies DRIO Competitors POCI Competitors MODD Competitors STRR Competitors NRXS Competitors CLGN Competitors RVP Competitors VVOS Competitors NXL Competitors COCH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNRX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNRX Stock Alerts